These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 22002757)

  • 1. Diffusion-weighted and dynamic contrast-enhanced MRI in evaluation of early treatment effects during neoadjuvant chemotherapy in breast cancer patients.
    Jensen LR; Garzon B; Heldahl MG; Bathen TF; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2011 Nov; 34(5):1099-109. PubMed ID: 22002757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer.
    Ah-See ML; Makris A; Taylor NJ; Harrison M; Richman PI; Burcombe RJ; Stirling JJ; d'Arcy JA; Collins DJ; Pittam MR; Ravichandran D; Padhani AR
    Clin Cancer Res; 2008 Oct; 14(20):6580-9. PubMed ID: 18927299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diffusion-weighted magnetic resonance imaging for pretreatment prediction and monitoring of treatment response of patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Nilsen L; Fangberget A; Geier O; Olsen DR; Seierstad T
    Acta Oncol; 2010 Apr; 49(3):354-60. PubMed ID: 20397769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal study of the assessment by MRI and diffusion-weighted imaging of tumor response in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy.
    Sharma U; Danishad KK; Seenu V; Jagannathan NR
    NMR Biomed; 2009 Jan; 22(1):104-13. PubMed ID: 18384182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI.
    Johansen R; Jensen LR; Rydland J; Goa PE; Kvistad KA; Bathen TF; Axelson DE; Lundgren S; Gribbestad IS
    J Magn Reson Imaging; 2009 Jun; 29(6):1300-7. PubMed ID: 19472387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of diffusion-weighted imaging as an adjunct to contrast-enhanced breast MRI in evaluating residual breast cancer following neoadjuvant chemotherapy.
    Hahn SY; Ko EY; Han BK; Shin JH; Ko ES
    Eur J Radiol; 2014 Feb; 83(2):283-8. PubMed ID: 24315957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric magnetic resonance imaging for predicting pathological response after the first cycle of neoadjuvant chemotherapy in breast cancer.
    Li X; Abramson RG; Arlinghaus LR; Kang H; Chakravarthy AB; Abramson VG; Farley J; Mayer IA; Kelley MC; Meszoely IM; Means-Powell J; Grau AM; Sanders M; Yankeelov TE
    Invest Radiol; 2015 Apr; 50(4):195-204. PubMed ID: 25360603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of pathologic response to neoadjuvant chemotherapy in patients with breast cancer using diffusion-weighted imaging and MRS.
    Shin HJ; Baek HM; Ahn JH; Baek S; Kim H; Cha JH; Kim HH
    NMR Biomed; 2012 Dec; 25(12):1349-59. PubMed ID: 22566277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diffusion-weighted imaging in evaluating the response to neoadjuvant breast cancer treatment.
    Belli P; Costantini M; Ierardi C; Bufi E; Amato D; Mule' A; Nardone L; Terribile D; Bonomo L
    Breast J; 2011; 17(6):610-9. PubMed ID: 21929557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MRI measurements of tumor size and pharmacokinetic parameters as early predictors of response in breast cancer patients undergoing neoadjuvant anthracycline chemotherapy.
    Yu HJ; Chen JH; Mehta RS; Nalcioglu O; Su MY
    J Magn Reson Imaging; 2007 Sep; 26(3):615-23. PubMed ID: 17729334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring neoadjuvant chemotherapy in breast cancer patients: improved MR assessment at 3 T?
    Heldahl MG; Lundgren S; Jensen LR; Gribbestad IS; Bathen TF
    J Magn Reson Imaging; 2011 Sep; 34(3):547-56. PubMed ID: 21761463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring breast cancer response to neoadjuvant systemic chemotherapy using parametric contrast-enhanced MRI: a pilot study.
    Chou CP; Wu MT; Chang HT; Lo YS; Pan HB; Degani H; Furman-Haran E
    Acad Radiol; 2007 May; 14(5):561-73. PubMed ID: 17434070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dynamic contrast enhanced MRI in monitoring early response of locally advanced breast cancer to neoadjuvant chemotherapy.
    Pickles MD; Lowry M; Manton DJ; Gibbs P; Turnbull LW
    Breast Cancer Res Treat; 2005 May; 91(1):1-10. PubMed ID: 15868426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic resonance imaging enhancement features before and after neoadjuvant chemotherapy in patients with breast cancer: a predictive value for responders.
    Kang DK; Kim TH; Han TS; Kim KS; Yim H
    J Comput Assist Tomogr; 2013; 37(3):432-9. PubMed ID: 23674017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.
    Yoshizako T; Wada A; Hayashi T; Uchida K; Sumura M; Uchida N; Kitagaki H; Igawa M
    Acta Radiol; 2008 Dec; 49(10):1207-13. PubMed ID: 19031184
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts.
    Moestue SA; Huuse EM; Lindholm EM; Bofin A; Engebraaten O; Mælandsmo GM; Akslen LA; Gribbestad IS
    J Magn Reson Imaging; 2013 Nov; 38(5):1043-53. PubMed ID: 23908122
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative evaluation of breast cancer response to neoadjuvant chemotherapy by diffusion tensor imaging: Initial results.
    Furman-Haran E; Nissan N; Ricart-Selma V; Martinez-Rubio C; Degani H; Camps-Herrero J
    J Magn Reson Imaging; 2018 Apr; 47(4):1080-1090. PubMed ID: 28901594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of breast cancer response to neoadjuvant chemotherapy: is volumetric MRI a reliable tool?
    Lorenzon M; Zuiani C; Londero V; Linda A; Furlan A; Bazzocchi M
    Eur J Radiol; 2009 Jul; 71(1):82-8. PubMed ID: 18472240
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI.
    Langer DL; van der Kwast TH; Evans AJ; Trachtenberg J; Wilson BC; Haider MA
    J Magn Reson Imaging; 2009 Aug; 30(2):327-34. PubMed ID: 19629981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer using diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.
    Xu HD; Zhang YQ
    Neoplasma; 2017; 64(3):430-436. PubMed ID: 28253722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.